Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2-methylthio-AMP
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
**2-methylthio-AMP** is a synthetic nucleotide analog and a selective, direct antagonist of the P2Y12 receptor. It acts as an inhibitor of ADP-dependent platelet aggregation by targeting the P2Y12 receptor, which plays a critical role in platelet activation. The compound is primarily utilized as a research tool to study platelet function and purinergic signaling and is not approved for therapeutic use in humans. Its structure is a modified adenosine monophosphate with a methylthio group at the 2-position of the adenine moiety[1][6][9].
- Other names
- 2-methylthioadenosine 5-monophosphate2-methylthioadenosine 5'-monophosphate2-methylthioadenosine 5'-phosphatepoly(2'-methylthioadenylic acid)
02
Targets
P2Y12 (Purinergic P2Y12 receptor)
Beyond the preview
Go deeper on 2-methylthio-AMP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 2-methylthio-AMP.